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EEL Rupture (16) Normal EEL (21) P value *p<O.O5, tp<O.Ol (unpaired t-test, compared to previous step) 
Plaque Neovessels (total count) 52 * 32 
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1149-195 Physiologic Assessment of Serial Lesions: Comparison 
of Present Methodologies 
A P (mmHg) v (cm/s) FFR CVR SRv(mmHg/cm/s) 
h-x/ 35.6 f 16.6 30.3 * 18.5 0.62 * 0.17 1.66 f 0.54 2.05 zt 2.17 
&?/loon 16.1 * 9.07 44.6 * 11.2t 0.60~O.lOt 2.14 * 0.36’ 0.46 * 0.3lt 
Stenf 11.2 * 7.9 59.1 f 19.0* 0.88 * 0.09 2.88 * 0.62t 0.22 f 0.19 
UPstent 11.2 * 3.3 61.6 f 20.3 0.6a*o.l1 2.76 * 0.40 0.21 r 0.25 
Luis Gruberq Eugenia Nikolsky, Hylton Miller, Carlo Di Mario, Martin Leon, Rafael 
Beyar, Rambam Medical Center, Haifa, Israel, Tel Aviv Medical Center, Tel Aviv, Israel POSTER SESSION 
Background: FFR is a well-established hemodynamic parameter for physiological 
assessment of the severity of a single coronary lesion. We compared a novel algorithm 
to assess the individual FFR of each lesion in a vessel with serial lesions to the current 
method which requires multiple hyperemic injections and wedge pressure measure- 
ments. 
Methods: 26 patients undergoing intervention for two (n=24) or three (n=2) tandem 
lesions were studied. Basal and hyperemic pressure curves were measured distal to 
each of the serial stenoses. At least one lesion was treated in each patient based on 
angiographic evaluation. Wedge pressure was measured during balloon inflation for 
treatment of one of the lesions and used lo calculate the wedge based value of FFR 
(FFRwedge). FFRsmarlflow was derived from rest pressure across each of the serial 
lesions and one hyperemic pressure across all lesions. 
Results: Individual FFR obtained by both methods were highly correlated (wO.96, 
p<O.OOl). The correlation was significant for both the proximal lesion (r=0.93, pcO.001) 
and for the distal lesion (r= 0.99, pcO.001). Combining the proximal and distal lesions, 
there was no significant difference between the two methods (p= 0.733). 
Conclusions: FFRsmartflow allows real-time and accurate evaluation of lesion specific 
FFR in vessels with multiple serial lwons with only baseline pressure measurements 
between lesions and one distal measurement with adenosine injection. 
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1150-178 First Clinical Experience With 17- Estradiol-Eluting 
BiodivYsio Matrix LO Stent to Prevent Restenosis in 
De-Novo Native Coronary Arteries: Six-Month Clinical 
Outcomes and Angiographic Follow-Up From the 
EASTER Trial 
Alexandre A. Abizaid, Gishel New, Andrea S. Abizaid, Marco Costa, Vinicius Vaz, 
Nicholas Kipshidze, Rodolfo Staico, Faust0 Feres, Roxana Mehran, lbraim Pinto, Gary 
Roubin, Sriram lyer, Jefrrey Moses, Marlin Leon, Amanda Sousa, Jose Eduardo M. 
Sousa, Institute Dante Pauanese of Cardiology, Sao Paula, Brazil, Cardiovascular 
Research FoundationlLenox Hill Hospital, New York, NY 
I- 
R=0.96 
0.9 - 
o -first lesion, R=0.93 
*- second lesioh, R=0.99 
Background: A recent study in the porcine coronary model demonstrated that 173 
sstradiol-eluting atents reduce neointimal formation by 40%. Whether 17-p estradiol has 
a similar vasculoprotective effect in the clinical setting is not known. 
Objective: To determine the safety of 17-p estradiol-eluting PC-coated stent (Bidi- 
vysioTM) in the treatment of de nova native coronary stenosis.: and the efficacy of this 
strategy on B-month binary restenosis and late loss as assessed by angiography. 
Methods: Thirty patients were studied in this prospective pilot registry. All pawn& 
received a single 15 or 16 mm drug-eluting Bidivysio TM stent. The average drug concen- 
tration was approximately 2.54p@mm’ as previously studied in the animal model. 
Results: Mean age was 61+12 years, 70% were men, 10% diabetics, 27% had hyperc- 
holesterolemia, and 44% previous MI. Lesion length was 9.1+2.4mm, and reference yes- 
sel diameter was 2.76+0.56mm. Angiographic results are shown in table: 
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Post intervention In-stent In-segment 
. MLD (mm) 2.44 * 0.52 2.04 f 0.43 
. Diameter stenosis (%) 13.6 * 10.4 23.4 * 10.9 
Follow-up 
1149-196 The Importance of Combined Pressure and Flow 
Velocity Measurements to Evaluate the Hemodynamic 
Effect of Percutaneous Coronary Interventions 
Maria Siebes, Ban-Jan Verhoeff, Martijn Meuwissen, Jos A. Spaan, Jan J. Piek, 
Academic Medical Center, Amsterdam, The Netherlands 
. MLD (mm) 1.69 * 0.57 1.76 zt 0.56 
_ Diameter stenosis (%) 28.2 * 14.6 30.5 + 14.9 
_ Late loss (mm) 0.54 + 0.44 0.31 * 0.38 
Binary restenosis occurred in 2 pts (6.6%) and ischemic driven target vessel revascular- 
izatlon in one (3.3%) with no additional major adverse cardiac events 
Conclusion: The implantafion of 17-p estradiol-eluting BiodlvysioTM stent was safe and 
associated with low binary restenosis and clinical recurrence. These data suppod the 
antiproliferative properties of estrogen and warrant further investigation in a larger ran- 
domized trial. 
Background: We simultaneously assessed distal flow velocity (v) and pressure with a 
novel 0.014” dual-sensor guide wire to determine the magnitude and sequence of hemo- 
dynamic changes that contribute to the outcome of percutaneous coronary intervention 
(PCI). 
Methods: Aortic pressure, Y, and distal pressure were measured after an i.c. bolus of 
adenosine in 12 patients with a single de nova lesion (56.4 * 12.5% diameter stenosis) 
before and after stepwise executed PCI (balloon angioplasiy, stenting and upsized stew 
ing guided by intravascular ultrasound). Pressure gradient (AP = aortic-distal pressure) 
and vat maximal hyperemia were compared per intervention step, as well as descriptors 
of functional stenosis severity, i.e., fractional (FFR) and coronary (CVR) flow reserve. 
and hyperemic stenosis resistance index (SRv=AP/v). 
Results: An initial large decrease inAP was followed by non-significant changes. In con- 
trast, v continued to increase significantly after the initial step. Upsized stenting caused 
variable results and slightly reduced CVR. Pressure-based parameters were least sensi- 
tive after the initial dilation, while SRv combined the sensitivity of AP and Y for all steps of 
PCI-induced hemodynamic changes. 
Conclusion: Stepwise executed PCI affects AP and v to variable degrees, with changes 
in pressure-based variables diminishing quickly. Assessment of PCI in hemodynamic 
terms benefits from combining pressure and velocity information and SRv may thus pro- 
vide a valuable prognostic tool. 
1150-179 Estradiol Coated Stents for the Prevention of 
Restenosis in Native Coronary Arteries: Results From 
the Randomized Multicentric Study EASTER 
Flavio Airoldi, Carlo Di Mario, Goran Stankovic, Carlo Briguori, Patrizia Presbitero. Flavio 
Ribichini, Vaaailia Spanos, Matte0 Montorfano, Angela Ferrari, Antonio Colombo, San 
Raffaele Hospital, EM0 Centro Cuore Columbus, Universita’ di Novara, lstituto Clinic0 
Humanitas, Milan, Italy 
Introduction: In vitro and animal models indicate that lip-&radio1 inhibits intimal smooth 
muscle cell proliferation and migration and accelerates re-endothelization after PTCA. 
This study prospectively and randomly compares stents loaded with lip-&radio1 (Biodi- 
vYsio DD Matrix, Biocompatibles, Galway, Ireland) to bare metal stents (BiodwYsio OC) 
in reducing restenosis rate. Methods we repolt the in-hospital and l-month follow-up 
(FU) results of the 2 different type of stents in de nova lwons located on native coronary 
arteries. In the study 61 patients with 111 lesions 54 (46%) in the estrogen arm and 57 
(52%) in the control arm. Complex lesions (82, C type ACClAHA) were 42% and 44% in 
the estrogen and in the control arm respectively (p=n.s.). No statistically significant differ- 
ences were noted between the 2 groups in baseline angiographic measurements (basal 
ref. diam. 2.69r 0.60 mm vs 2.95* 0.57 mm; MLD 0.97i 0.61 mm vs 1.02~ 0.56 mm: 
lesion length 11.7* 6.5 mm vs 13.9+ 9.6 mm I” the estrogen and in the control group 
respectively). nor after stenting (Final MLD 0.97+ 0.61 mm vs 1.02* 0.56 mm m the 
estrogen and in the control group respectively). After discharge, all patients have been 
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treated with double antiplatelet therapy for 3 months. Results angiographic success was 
obtained in all cases. During the hospital there were no death or repeat revasculariza- 
tions. Non Q-wave myocardial infarction (MI) occurred in 2 (2%) cases in the control arm 
(p=n.s.). After 1 months, no patient died. One patients in the estrogen arm had a non-Q 
wave MI 3 days after the procedure and target lesion revascularization with re-PTCA was 
repeated. All the patients have been scheduled for a 6-month angiographic FU that will 
be available at the time of presentation.Conclusions Stenting lesions on native coronary 
arteries with the estrogen coated stents is safe and is associated with high procedural 
success rate. In hospital course and i-month FU Indicate that estrogen coating stents do 
not seem to increase the risk of acute or sub-acute stent thrombosis compared to bare 
metal stent. The efficacy of this therapy in reducing restenosis rate will be assessed 
when the 6-months angiographic FU results will be available. 
1150-182 Vessel Size, Stent Strut Thickness, and Restenosis 
After Coronary Stem Placement: A Subgroup Analysis 
of the Randomized ISAR-STEREO-2 Trial 
Helmut Schiihlen, Adnan Kastrati, Julinda Mehilli, Jdrg Hausleiter. Jiirgen Pache, Josef 
Dirschinger, Albert Schbmig, Deutsches Herzzentrum. Munich, Germany, 1. Med. Klinik 
rechts der Isar, Munich, Germany 
1150-l 80 Stent-Based Programmable Erodable Polymer Drug 
Release Systems Are Nontoxic in Porcine Arteries 
Douqal McClean Saibal Kar. Taku Honda, Michael C. Fishbein, Neal L. Eigler, Frank 
Litvack. Cedars-Sinai Medical Center, Los Angeles, CA 
Potential drugs for vascular delivery have variable kinetic release requirements. Some 
first generation drug eluting stents have utilized non-erodable polymers and fixed kinet- 
ics, which may be responsible for late malapposition and restenosis. Bioerodable poly- 
mers positioned within the volume of a stent strut may be metabolized without tissue 
toxicity or malapposition. We evaluated configurations of the Conor stent with differing 
polymer volumes and degradation rates for restenosis and tissue toxicity. 
Methods and Results: The Conor stew has honey-combed metallic strut elements that 
contain automated programmable inlaid layers of bioerodable Polylactide-co-glycolide 
(PLGA). Degradation rates were manipulated by altering the PLGA co-monomer ratio 
and molecular weight. Three low volume PLGA groups with different in-vitrodegradation 
rates (21 to 180 days), one high volume PLGA group (21 days), and bare metal stent 
controls were randomly implanted !n the LAD, RCA and superficial femoral arteries (n=40 
stents) in a 30 day porcine model (n=12 pigs). Mean coronary injury scores (range: 1.1 to 
1.4) did not differ between the five groups. Tissue sections preserving metal and polymer 
architecture showed small but significant differences in polymer degradation rate (89% 
vs 78% in fast vs slow groups, pcO.05). Increasing the polymer volume 4-fold slowed the 
degradation rate to near zero. Blinded histologic scoring showed a neoendothelium, min- 
imal inflammation, foreign body reaction or neointimal fibrin and complete healing in all 
groups. NO medial necrws or stent strut malapposition was seen. Quantitative angiogra- 
phy and histomorphometry showed no difference in restenosis parameters versus bare 
metal controls. 
6ackground:The ISAR-STEREO-2 tnal has shown that stent strut thickness has a sig- 
nificant Impact on long-term outcome, with lower restenosis rates for thinner strut stents. 
This effect was seen in a comparison of 2 stents with different design, the thin-strut 
Guidant RX MultiLink and the thick-strut Cordis 8X Veloccty Small vessels (<2.8mm) 
have higher restenosis rates, and although some trials in small vessels have shown a 
significantly lower restenosis rate after stenting compared to PTCA, others have failed to 
show such benefit, including the ISAR-SMART trial using the MultiLink. Goal of the 
present analysis was therefore to differentlate the results of ISAR-STEREO-2 with 
respect to vessel size. 
Methods: All 611 patients randomized I” ISAR-STEREO-2 were included in this analy- 
sis. Results for patients with target vessels <2.8mm (n=262) were compared to those 
with large vessels (Z2.8mm; n=349). 
Results: Baseline clinical and angiographic characteristics did not differ significantly 
between the 2 groups. The primary end point of ISAR-STEREO-E, angiographic resteno- 
sis rate at 6 mo., is illustrated in the graph. 
m MultiLink KIl Velocity 
Conclusions: PLGA degradation rates are controllable but very less than predlcted in- 
vitro and are volume dependent. Erodable PLGA polymers positioned within the steni 
struts are non toxic and suitable for the controlled elution of bioactive substances. 
0 
1150-181 Stent Coated With Nitroxyl Groups for Reduction of 
Neointimal Hyperplasia in a Porcine Coronary Stent 
Model 
e2.8mm >2.8mm 
Yanminq Huanq, Xiaoshun Liu, Shengqiao Li, Lan Wang, Eric Verbeken. Ivan De 
Scheerder, University of Leuven, Leuven. Belgium 
Background: Coronary stent surface modification can improve the biocompatibility of a 
stent. Nrtroxides have shown a wide range of biological effects like suppressing free rad- 
ical driven reactions to maintain cell functions. The objectives of this study was to evalu- 
ate the efficacy of a biodegradable polymer coated stent loaded with nitroxyl groups on 
in-stent neomtimal hyperplasia. 
Methods: Bare stainless steel stents (Genie stents, Blue Medical Devices, The Nether- 
lands), loaded 50% (W%) nitroxyl groups ( Tempo Amine, Blue Medical Devices, The 
Netherlands) biodegradable elastomeric poly(ester-amide)(co-PEA) polymer dipcoated 
stents and control polymer coated stents were randomly implanted into porcine coronary 
arteries. Arterial segments were selected to achieve a balloon to artery ratio 1.5-l .2:1. Al 
5 days (4 stents for each group) and 6 weeks (bare n=8, both polymer coated and 50% 
Tempo loaded stents n=16) follow-up, histomorphometric analysis was performed on 
proximal, middle and distal parl of each stent segment. 
Results: Histomorphometric analysis showed that the bare stems, polymer-coated stents 
and Tempo loaded stents elicited a stmilar tissue response at 5 days follow-up. At 6 
weeks follow-up, the peri-strut inflammation of the polymer coated stents (1.03+0.06 vs 
1.09+0.14, P<O.OS) and Tempo loaded stents(l.O2+0.05 vs 1.09*0.14, PcO.01) were 
significantly lower than the bare stents. Arterial injury of bare stents was significantly 
higher than the polymer coated stems (0.33eO.21 vs 0.62iO.46, PcO.01) and Tempo 
loaded stents (0.34+0.23 vs 0.62+0.46,P<O.O1). Compared to the bare stents, the neoin- 
timal hyperplasis. and area stenosis of polymer coated stents (1.41?0.61 vs 1.78kO.79 
mm2; 25+11 vs 35+23 %; PqO.05) and Tempo loaded stems (1.27t0.42 vs 1.78*0.79 
mm2; 24*8 vs 35+23 %; P<O.Ol) were significantly decreased. The neointimal hyperpla- 
sia of Tempo loaded stems was the lowest. 
Conclusion: These co-PEA polymer stent coating showed a biocompatible performance 
and could decrease the neointimal hyperplasia at 6 weeks follow-up compared to bare 
stents. Loading of the polymer wth nitroxyl groups could further suppress the neomtimal 
formation. 
Conclusions: This subgroup analysis of ISAR-STEREO-2 shows that restenosis rates 
of the thick-strut Velocity do not differ according to vessel size. The advantage the thin- 
strut stent in this trial, the MultiLink, is for the most part limited to large vessels. This anal- 
ysis suggests that beyond strut thickness, different stent design features may play a dif- 
ferent role dependent on vessel size. 
1150-183 First Use of a Novel Cobalt Chromium Coronary Stent in 
Humans: Clinical and Angiographic Outcomes 
Dean J. Kereiakes, David Alan Cox, James Hermiller, Mark Midei. William Bachlnsky, 
Dean Nukta, Martin Leon, Stanley E. Fink, Linda Marin, Alexandra Lansky, The Lindner 
Center/Ohio Heart Health Center, Cincinnati, OH 
The evolution of an “ideal” stent platform remains critically Important in the era of drug 
eluting stents. Stem strut thickness and alloy may influence device profile, flexibility, 
deliverability, vwbility and radial strength. A novel thin strut (0.0032”) cobalt chromium 
MULTI-LINK (Guidant Corporabon) VISIONTM stent (n=294; lengths 8, 12, 15, 18, 23,28 
mm; diameters 3.0, 3.5, 4.0 mm) was deployed in 267 pabents (age 64 years, 68% male, 
23% diabetes) with a single de now native target vessel lesion k 25 mm length) in a 
multi-center international registry. Anglographic and clinical outcomes for the MULTI- 
LINK VISIONTM stents are compared with those previously observed for the TETRATM 
and PENTATM MULTI-LINK@stents. 
Conclusiorx This novel thin strut cobalt chromium MULTI-LINK VISION TM stent demon- 
strates excellent clinical performance charactenstics with reduced late loss and resteno- 
sis compared with prior MULTI-LINK@ stents. 
